13F Holdings
中文EN

CHRS Coherus Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—

Margins

Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%

Returns

ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x

Leverage & solvency

Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$42.17M$26.39M$257.24M$211.04M$326.55M
Cost of revenue$13.81M$8.73M$158.99M$70.08M$57.59M
Gross profit$28.36M$17.66M$98.25M$140.96M$268.96M
R&D expense$108.89M$91.83M$109.44M$199.36M$363.11M
SG&A expense$100.60M$125.48M$192.01M$198.48M$169.71M
Operating income-$181.13M-$199.65M-$203.20M-$256.88M-$263.86M
Interest expense$9.00M$10.73M$40.54M$32.47M$22.96M
Pretax income-$183.12M-$215.39M-$238.27M-$291.75M-$287.10M
Income tax$0$0-$380,000$0$0
Net income$168.02M$28.51M-$237.89M-$291.75M-$287.10M
EBITDA-$179.83M-$198.05M-$200.00M-$253.28M-$260.36M
EPS (basic)1.430.25-2.53-3.76-3.81
EPS (diluted)1.430.25-2.53-3.76-3.81
Weighted avg. shares (diluted)117.14M114.55M94.16M77.63M75.45M
Balance sheet
Cash & equivalents$88.88M$126.25M$103.34M$63.55M$417.19M
Short-term investments$83.25M—$14.86M$128.13M—
Receivables$17.82M$111.32M$260.52M$109.96M$123.02M
Inventory$3.17M$4.21M$62.60M$38.79M$37.64M
Current assets$206.71M$341.58M$475.63M$381.23M$602.32M
PP&E, net$1.34M$2.58M$5.12M$8.75M$7.81M
Goodwill——$943,000$943,000$900,000
Intangibles$20.00M$24.79M$41.87M$5.93M$3.56M
Total assets$258.34M$448.53M$629.60M$480.85M$679.33M
Current liabilities$140.39M$282.98M$331.77M$138.69M$165.33M
Total liabilities$197.33M$580.52M$823.03M$618.26M$581.61M
Shareholders' equity$61.01M-$131.99M-$193.43M-$137.42M$97.73M
Shares outstanding121.15M115.61M112.22M78.85M76.93M
Cash flow statement
Operating cash flow-$138.51M-$20.44M-$174.88M-$241.12M-$37.43M
Capital expenditure——$286,000$2.04M$1.29M
Free cash flow——-$175.17M-$243.16M-$38.72M
Investing cash flow$375.09M$230.32M$144.64M-$166.85M-$138.41M
Financing cash flow-$273.70M-$186.97M$69.60M$54.33M$51.88M
Depreciation & amortization$1.30M$1.60M$3.20M$3.60M$3.50M
Stock-based compensation$16.97M$27.80M$43.11M$50.74M$51.36M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.